New markers of oxidative damage to macromolecules

Journal of Medical Biochemistry

Volumn 27, Issue 1, 2008, Pages 1-16

  Čolak, Emina ^a,b  

^a CCS   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

Biomarkers; Carbonyl stress; DNA; Free radicals; Lipid peroxidation; Oxidative modification of lipids; Proteins

Indexed keywords

3 CHLOROTYROSINE; 3 NITROTYROSINE; 4 HYDROXYNONENAL; 4,5 DIHYDROXYDECENAL; ACROLEIN; ADVANCED GLYCATION END PRODUCT; ALDEHYDE; ALDEHYDE DERIVATIVE; ALKADIENE; CARBONYL DERIVATIVE; CYSTEINE; FREE RADICAL; HEXANOYLLYSINE; HYDROCARBON; HYDROXYL RADICAL; ISOPROSTANE; LIPID HYDROPEROXIDE; LYSINE DERIVATIVE; MALONALDEHYDE; METHIONINE; NITROGEN; OXIDIZING AGENT; OXYGEN; PEROXYNITRITE; TYROSINE; UNCLASSIFIED DRUG;

ACIDITY; ACUTE HEART INFARCTION; AMINO ACID METABOLISM; AMINO ACID SEQUENCE; ATHEROSCLEROSIS; CATALYSIS; CELL MEMBRANE; CHEMICAL BOND; CHEMICAL INTERACTION; CORONARY ARTERY DISEASE; COVALENT BOND; DISEASE COURSE; DNA BINDING; DNA DAMAGE; ELECTROSPRAY MASS SPECTROMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; GAMMA RADIATION; GENE ACTIVATION; GENE MUTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIPID PEROXIDATION; LIQUID CHROMATOGRAPHY; LUPUS ERYTHEMATOSUS; MACROMOLECULE; MONOCYTE; NEUTROPHIL; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN DNA INTERACTION; PROTEIN MODIFICATION; PROTEIN SECONDARY STRUCTURE; PROTEIN STABILITY; PROTEIN TERTIARY STRUCTURE; REGULATORY MECHANISM; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC SCLEROSIS; VISCOSITY;

EID: 41849089367     PISSN: 14528258     EISSN: 14528266     Source Type: Journal    
DOI: 10.2478/v10011-007-0049-x     Document Type: Review

References (143)

1. Commoner B, Townsed J, Pake GE. Free radicals in biological materials. Nature 1954;174: 689-91.
2. Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol 1956; 11: 298-300.
3. Harman D. The aging process. Proc Natl Acad Sci USA 1981; 78: 7124-8.
4. McCord JM, Fridovich I. Superoxide dismutase: an enzymic function for erythrocuprein (hemocuprein). J Biol Chem 1969; 244: 6049-55.
5. Beckman KB, Ames BN. The free radical theory of aging matures. Physiol Rev 1998;78: 547-81.
6. Mittal CK, Murad F. Activation of guanylate cyclase by superoxide dismutase and hydroxyl radical: a physiological regulator of guanosine 3′,5′-monophosphate formation. Proc Natl Acad Sci USA 1977; 74: 4360-4.
7. Ignarro LJ, Kadowitz PJ. The pharmacological and physiological role of cyclic GMP in vascular smooth muscle relaxation. Ann Pharmacol Toxicol 1985; 25: 171-91.
8. Radomski MW, Palmer RMJ, Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987; 92: 639-46.
9. Roth S, Dröge W. Regulation of T cell activation and T cell growth factor (TCGF) production by hydrogen peroxide. Cell Immunol 1987; 108: 417-24
10. Keyse SM, Tyrrell RM. Heme oxygenase in the major 32-kDa stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide and sodium arsenite. Proc Natl Acad Sci USA 1989; 86: 99-103
11. Storz G, Tartaglia LA, Ames BN. Transcriptional regulator of oxidative stress-inducible genes: direct activation by oxidation. Science 1990; 248:189-94
12. Schreck R, Albermann K, Baeuerle PA. Nuclear factor kappa B: an oxidative stress responsive transcription factor of eucaryotic cells. Free Radic Res Commun 1992; 17: 221-37.
13. Dröge W. Free radicals in the physiological control of cell function. Physiol Rev 2002; 82: 47-95.
14. Čolak E, Majkić-Singh N, Stanković S, Djordjević B Predrag, Srećković-Dimitrijević V, Lalić K, Lalić N. The effect of hyperglycemia on the values of antioxidative parameters in type 2 diabetic patients with cardiovascular complications. Jugoslov Med Biohem 2006; 25 (2): 173-9.
15. Čolak E, Majkić-Singh N, Stanković S, Srećković-Dimitrijević V, Crossed D signorCrossed d signević PB, Lalić K, Lalić N. Parameters of antioxidative defense in type 2 diabetic patients with cardiovascular complications. Ann Med 2005; 37: 613-20.
16. Crossed D signorCrossed d signević VB, Pavlović DD, Kocić GM. Biohemija slobodnih radikala, Niš 2000.
17. Halliwell B, Gutteridge JMC. Lipid peroxidation: a radical chain reaction. 1985; 189-93. In: Free radicals in biology and medicine, Oxford: Clarendon Press, 1985.
18. Karayalcin SS, Sturbaum CW, Wachman JT, Cha JH, Powell DW. Hydrogen peroxide stimulates rat colonic prostaglandin production and alters electrolyte transport. J Clin Investig 1990; 86: 60-8.
19. Korsmeyer SJ, Yin XM, Oltvai ZN, Veis-Novack DJ, Linette GP. Reactive oxygen species and the regulation of cell death by the Bcl-2 gene family. Biochim Biophys Acta 1995; 1271: 63-6.
20. Kagan VE. Lipid peroxidation in biomembranes. Florida: CRC Press, Inc. Boca Raton 1988.
21. Aust SD, Morehouse LA, Thomas CE. Role of metals in oxygen radical reactions. J Free Radic Biol Med 1985; 1: 3-25.
22. Fong KL, McCay PB, Poyer JL, Kerle BB, Misra H. Evidence that peroxidation of lysosomal membranes is initiated by hydroxyl free radicals, produced during flavin enzyme activity. J Biol Chem 1973; 248: 7792-7.
23. Gargner HW. Oxygen radical chemistry of polyunsaturated fatty acids. Free Radic Biol Med 1989; 7: 65-86.
24. Girotti AW. Lipid hydroperoxide generation turnover, and effector action in biological systems. J Lipid Res 1998; 39: 1529-42.
25. Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A. Biomarkers of oxidative damage in human disease. Clin Chem 2006; 52: 601-23.
26. Stocker R, Keaney JF, Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84: 1381-478.
27. Berliner J, Heinecke JW. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med 1996; 20: 707-27.
28. Slatter DA, Bolton CH, Bailey AJ. The importance of lipid-derived malondialdehyde in diabetes mellitus. Diabetologia 2000; 43: 550-7.
29. Heinecke JW. Oxidized amino acids: culprits in human atherosclerosis and indicators of oxidative stress. Free Radic Biol Med 2002; 32: 1090-101.
30. Yoneyama Y, Sawa R, Suzuki S, Doi D, Yoneyama K, Otsubo Y, et al. Relationship between plasma malondialdehyde levels and adenosine deaminase activities in preeclampsia. Clin Chim Acta 2002; 322: 169-73.
31. Wood LG, Gibson PG, Garg ML. Biomarkers of lipid peroxidation, airway inflammation and asthma. Eur Respir J 2003; 21: 177-86.
32. Barnham KJ, Masters CL, Bush AI. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 2004; 3: 205-14.
33. Uchida K. 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog Lipid Res 2003; 42: 318-43.
34. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 1991; 11: 81-128.
35. Eckl PM, Ortner A, Esterbauer H. Genotoxic properties of 4-hydroxyalkenals and analogous aldehydes. Mutat Res 1993; 290: 183-92.
36. Carini M, Aldini G, Facino RM. Mass spectrometry for detection of 4-hydroxy-trans-2-nonenal (HNE) adducts with peptides and proteins. Mass Spectrom Rev 2004; 23: 281-305.
37. Parola M, Bellomo G, Robino G, Barrera G, Dianzani MU. 4-Hydroxynonenal as a biological signal: molecular basis and pathophysiological implications. Antioxid Redox Signal 1999; 1: 255-84.
38. Feng Z, Hu W, Tang MS. Trans-4-hydroxy-2-nonenal inhibits nucleotide excision repair in human cells: a possible mechanism for lipid peroxidation-induced carcinogenesis. Proc Natl Acad Sci U S A 2004; 101: 8598-602.
39. Siems W, Grune T. Intracellular metabolism of 4-hydroxynonenal. Mol Aspects Med 2003; 24: 167-75.
40. Uchida K, Stadtman ER. Modification of histidine residues in proteins by reaction with 4-hydroxynonenal. Proc Natl Acad Sci USA 1992; 89: 4544-8.
41. Butterfield DA. Amyloid β-peptide(1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. Free Radic Res 2002; 36: 1307-13.
42. Butterfield DA, Castegna A, Lauderback CM, Drake J. Evidence that amyloid β-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol Aging 2002; 23: 655-64.
43. Shao B, O'Brien KD, McDonald TO, Fu X, Oram JF, Uchida K, et al. Acrolein modifies apolipoprotein-I in the human artery wall. Ann N Y Acad Sci 2005; 1043: 396-403.
44. Ranganna K, Yousefipour Z, Nasif R, Yatsu FM, Milton SG, Hayes BE. Acrolein activates mitogen-activated protein kinase signal transduction pathways in rat vascular smooth muscle cells. Mol Cell Biochem 2002; 240 (1-2): 83-98.
45. Liu-Snyder P, McNally H, Shi R, Borgens RB. Acrolein-mediated mechanisms of neuronal death. J Neurosci Res 2006; 84 (1): 209-18.
46. Lambert C, Li J, Jonscher K, Yang TC, Reigan P, Quintana M, et al. Acrolein inhibits cytokine gene expression by alkylating cysteine and arginine residues in the NF-kappaB1 DNA binding domain. J Biol Chem 2007; 282 (27): 19666-75.
47. Montuschi P, Barnes PJ, Roberts LJ II. Isoprostanes: markers and mediators of oxidative stress. The FASEB J 2004; 18: 1791-800.
48. Roberts, LJ, Morrow, JD. Measurement of F2-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 2000; 28: 505-13.
49. Pryor WA, Stanely JP, Blair E. Autoxidation of polyunsaturated fatty acids. A suggested mechanism for the formation of TBA-reactive materials from prostaglandin-like endoperoxides. Lipids 1976; 11: 370-9.
50. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ II. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990; 87: 9383-7.
51. Taber DF, Morrow JD, Roberts LJ II. A nomenclature system for the isoprostanes. Prostaglandins 1997; 53: 63-7.
52. Morrow JD, Awad JA, Boss HJ, Blair IA, Roberts LJ II. Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proc. Natl Acad Sci USA 1992; 89: 10721-5.
53. Morrow JD, Roberts LJ II. The isoprostanes: unique bioactive products of lipid peroxidation. Prog Lipid Res. 1997; 36: 1-21.
54. Chen Y, Morrow JD, Roberts LJ II. Formation of reactive cyclopentenone compounds in vivo as products of the isoprostane pathway. J Biol Chem 1999; 274: 10863-8.
55. Brame CJ, Salomon RG, Morrow JD, Roberts LJ II. Identification of extremely reactive γ-ketoaldehydes (isolevuglandins) as products of the isoprostane pathway and characterization of their lysyl protein adducts. J Biol Chem 1999; 274: 13139-46.
56. Roberts LJ II, Moore KP, Zackert WE, Oates JA, Morrow JD. Identification of the major urinary metabolite of the F2-isoprostane 8-iso-prostaglandin F2 in humans. J Biol Chem 1996; 271: 20617-20.
57. Roberts LJ II, Montine TJ, Markesbery WR, Tapper AR, Hardy P, Chemtob S, et al. Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem 1998; 273: 13605-12.
58. Marnett LJ. Lipid peroxidation-DNA damage by malondialdehyde. Mutat Res 1999; 424: 83-95.
59. Wang M, Dhingra K, Hittleman WN, Liehr JG, De Andrade M, Li D. Lipid peroxidation-induced putative malondialdehyde-DNA adducts in human breast tissues. Cancer Epidemiol Biomarkers Prev. 1996; 5: 705-10.
60. Orioli M, Aldini G, Beretta G, Facino RM, Carini M. LC-ESI-MS/MS determination of 4-hydroxy-trans-2-nonenal Michael adducts with cysteine and histidine-containing peptides as early markers of oxidative stress in excitable tissues. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 827 (1): 109-18
61. Aldini G, Granata P, Carini M. Detoxification of cytotoxic alpha,beta-unsaturated aldehydes by carnosine: characterisation of conjugated adducts by electrospray ionization tandem mass spectrometry and detection by liquid chromatography/mass spectrometry in rat skeletal muscle. J Mass Spectrom 2002; 37 (12): 1219-28.
62. Borović S, Rabuzin F, Waeg G, Žarković N. Enzyme-linked immunosorbent assay for 4-hydroxynonenal-histidine conjugates. Free Radic Res 2006; 40 (8): 809-20.
63. Carini M, Aldini G, Beretta G, Arlandini E, Facino RM. Acrolein-sequestering ability of endogenous dipeptides: characterization of carnosine and homocarnosine/acrolein adducts by electrospray ionization tandem mass spectrometry. J Mass Spectrom 2003; 38 (9): 996-1006.
64. Zhang S, Villalta PW, Wang M, Hecht SS. Detection and quantitation of acrolein-derived 1,N2-propanodeoxyguanosine adducts in human lung by liquid chromatography-electrospray ionization-tandem mass spectrometry. Chem Res Toxicol 2007; 20 (4): 565-71.
65. Praticò D, Lawson JA, Rokach J, FitzGerald GA. The isoprostanes in biology and medicine. Trends Endocrinol. Metab 2001; 12: 243-7.
66. Wang Z, Ciabattoni G, Creminon C, Lawson J, FitzGerald GA, Patrono C, et al. Immunological characterization of urinary 8-epi-prostaglandin F2 excretion in man. J Pharmacol Exp Ther 1995; 275: 94-100.
67. Proudfoot J, Barden A, Mori TA, Burke V, Croft KD, Beilin LJ, et al. Measurement of urinary F2-isoprostanes as markers of in vivo lipid peroxidation. A comparison of enzyme immunoassay with gas chromatography/mass spectrometry. Anal Biochem 1999; 272: 209-15.
68. Gopaul NK, Halliwell B, Anggard EE. Measurement of plasma F2-isoprostanes as an index of lipid peroxidation does not appear to be confounded by diet. Free Radic Res 2000; 33: 115-27.
69. Gopaul NK, Zacharowski K, Halliwell B, Anggard EE. Evaluation of the postprandial effects of a fast-food meal on human plasma F2-isoprostane levels. Free Radic Biol Med 2000; 28: 806-14.
70. Cracowski JL, Durand T, Bessard G. Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications. Trends Pharmacol Sci 2002; 23: 360-6.
71. Helmersson J, Basu S. F2-Isoprostane excretion rate and diurnal variation in human urine. Prostaglandins Leukot Essent Fatty Acids 1999; 61 203-5.
72. Montuschi P. Indirect monitoring of lung inflammation. Nat Rev Drug Discov 2002; 1: 238-42.
73. Montuschi P, Barnes PJ. Analysis of exhaled breath condensate for monitoring airway inflammation. Trends Pharmacol Sci 2002; 23: 232-7.
74. Lynch SM, Morrow JD, Roberts LJ II, Frei B. Formation of non-cyclooxygenase-derived prostanoids (F2-isoprostanes) in plasma and low density lipoprotein exposed to oxidative stress in vitro. J Clin Invest 1994; 93: 998-1004.
75. Stadtman ER. Protein oxidation and aging. Free Radic Res 2006; 40 (12): 1250-8.
76. Stadtman ER. Role of oxidant species in aging. Curr Med Chem 2004; 11 (9): 1105-12.
77. Miyoshi N, Oubrahim H, Chock PB, Stadtman ER. Age-dependent cell death and the role of ATP in hydrogen peroxide-induced apoptosis and necrosis. Proc Natl Acad Sci USA 2006; 103 (6): 1727-31.
78. Requena JR, Levine RL, Stadtman ER. Recent advances in the analysis of oxidized proteins. Amino Acids 2003; (3-4): 221-6.
79. Van der Vliet A, Nguyen MN, Shigenaga MK, Eiserich JP, Marelich GP, Cross CE. Myeloperoxidase and protein oxidation in cystic fibrosis. Am J Physiol 2000; 279: L537-46.
80. Bota DA, Davies KJ. Protein degradation in mitochondria: implications for oxidative stress, aging and disease: a novel etiological classification of mitochondrial proteolytic disorders. Mitochondrion 2001; (1): 33-49.
81. Refsgaard HH, Tsai L, Stadtman ER. Modifications of proteins by polyunsaturated fatty acid peroxidation products. Proc Natl Acad Sci USA 2000; 97 (2): 611-6.
82. Stadtman ER, Levine RL. Oxidation of cellular proteins by beta-amyloid peptide. Neurobiol Aging 1999; 3: 331-42.
83. Stadtman ER, Levine RL. Free radical-mediated oxidation of free amino acids and amino acids residues in proteins. Amino Acids 2003; 3-4: 207-18.
84. Stadtman ER, Moskovitz J, Levine RL. Oxidation of methionine residues in proteins: biological consequences. Antioxid Redox Signal 2003; 5: 577-82.
85. Stadtman ER, Van Rommer H, Richardson A, Wehr NB, Levine RL. Methionine oxidation and aging. Biochim Biophys Acta 2005; 1703 (2): 135-40.
86. Dalle-Donne I, Scaloni A, Giustarini D, Cavarra E, Tell G, Lungarella G, et al. Proteins as biomarkers of oxidative stress in diseases: the contribution of redox proteomics. Mass Spectrom Rev 2005; 24: 55-99.
87. Davies MJ, Fu S, Wang H, Dean RT. Stable markers of oxidant damage to proteins and their application in study of human disease. Free Radic Biol Med 1999; 27: 1151-61.
88. Dalle-Donne I, Giustarini D, Colombo R, Rossi R, Milzani A. Protein carbonylation in human diseases. Trends Mol Med 2003; 9: 169-76.
89. Giulini C, Traaseth NJ, Davies KJ. Tyrosine oxidation products: analysis and biological relevance. Amino Acids 2003; (3-4): 227-32.
90. Koppenol WH, Moreno JJ, Pryor WA, Ischiropoulos H, Beckman JS. Peroxynitrite: a cloaked oxidant from superoxide and nitric oxide. Chem Res Toxicol 1992; 5: 834-42.
91. Richeson CE, Mulder P, Bowry VW, Ingold KU. The complex chemistry of peroxynitrite decomposition: new insights. J Am Chem Soc 1998; 120: 7211-9.
92. Dedon PC, Tannenbaum SR. Reactive nitrogen species in the chemical biology of inflammation. Arch Biochem Biophys 2004; 423: 12-22.
93. Ischiropoulos H. Biological selectivity and functional aspects of protein tyrosine nitration. Biochem Biophys Res Commun 2003; 305: 776-83.
94. Requena JR, Levine RL, Stadtman ER. Recent advances in the analysis of oxidized proteins. Amino Acids 2003; 25: 221-6.
95. Bohlender MJ, Franke S, Stein, Wolf G. Advanced glycation end products and the kidney. Am J Physiol Renal Physiol 2005; 289: 645-59.
96. Yamagishi S, Nakamura K, Imaizumi T. Advanced glycation end products (AGEs) and diabetic vascular complications. Curr Diabet Rev 2005; 1: 93-106.
97. Dyer DG, Dun JA, Thorpe SR, Bailie KE, Lyons TJ, McCance DR, et al. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 1993; 91: 2463-9.
98. Hein G, Wiegand R, Lehmann G, Stein G, and Franke S. Advanced glycation end-products pentosidine and N-carboxymethyllysine are elevated in serum of patients with osteoporosis. Rheumatology 2003; 42: 1242-6.
99. Suzuki D, Miyata T, Saotome N, Horie K, Inagi R, Yasuda Y, et al. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesion. J Am Soc Nephrol 1999; 10: 822-32.
100. Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J, et al. Isolation and characterization of binding proteins for advanced glycosylation end products from lung tissue which are present on the endothelial surface. J Biol Chem 1992; 267: 14987-97.
101. Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening. J Hypertens 2003; 21: 3-12.
102. Miyata T, Kurokawa K, Van Ypersele de Strihou C. Advanced glycation and lipoxidation end products: role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism. J Am Soc Nephrol 2000; 11: 1744-52.
103. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108: 949-55
104. Singh R, Bardou A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001; 44: 129-46.
105. Wautier JL, Schmidt AM. Protein glycation: a firm link to endothelial cell dysfunction. Circ Res 2004; 95: 233-8.
106. Wendt T, Tanji N, Guo J, Hudson BI, Bierhaus A, Ramasamy R, et al. Glucose, glycation and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol 2003; 14: 1383-95.
107. Miyata T, Fu MX, Kurokawa K, Van Ypersele de Strihou C, Thorpe SR, Baynes JW. Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: is there oxidative stress in uremia? Kidney Int 1998; 54: 1290-5.
108. Miyata T, Van Ypersele de Strihou C, Kurokawa K, Baynes JW. Alterations in non-enzymatic biochemistry in uremia: origin and significance of »carbonyl stress« in long-term uremic complications. Kidney Int 1999; 55: 389-99.
109. Niwa T, Katsuzaki T, Momoi T, Miyazaki T, Ogawa H, Saito A, et al. Modification of 2m with advanced glycation end products as observed in dialysis related amyloidosis by 3-DG accumulating in uremic serum. Kidney Int 1996; 49: 861-7.
110. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991; 325: 836-42.
111. Miyata T, Ueda Y, Shinzato T, Iida Y, Tanaka S, Kurokawa K, et al. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol 1996; 7: 1198-206.
112. Shacter E. Quantification and significance of protein oxidation in biological samples. Drug Metab Rev 2000; 32 (3-4): 307-26.
113. Dean RT, Fu S, Stocker R, Davies MJ. Biochemistry and pathology of radical-mediated protein oxidation. Biochem J 1997; 324: 1-18.
114. Stadtman ER, Berlett BS. Reactive oxygen mediated protein oxydation in aging and disease. Drug Metab Rev 1998; 30: 225-43.
115. Yan LJ, Lodge JK, Traber MG, Matsugo S, Packer L. Comparison between copper-mediated and hypochlorite-mediated modification of human low density lipoproteins evaluated by protein carbonyl formation. J Lipid Res 1997; 38: 992-1001.
116. Gaut JP, Yeh GC, Tran HD, Byun J, Henderson JP, Richter GM, et al. Neutrophils employ the myeloperoxidase system to generate antimicrobial brominating and chlorinating oxidants during sepsis. Proc Natl Acad Sci U S A 2001; 98: 11961-6.
117. Hazen SL, Heinecke JW. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest 1997; 99: 2075-81.
118. Duncan MW. A review of approaches to the analysis of 3-nitrotyrosine. Amino Acids 2003; 25: 351-61.
119. Tsikas D, Mitschke A, Suchy MT, Gutzki FM, Stichtenoth DO. Determination of 3-nitrotyrosine in human urine at the basal state by gas chromatography- tandem mass spectrometry and evaluation of the excretion after oral intake. J Chromatogr B 2005; 827: 146-56.
120. Levine RL, Wehr N, Williams JA, Stadtman ER, Shacter E. Determination of carbonyl groups in oxidized proteins. Methods Mol Biol 2000; 99: 15-24.
121. Stadtman ER, Moskovitz J, Berlett BS, Levine RL. Cyclic oxidation and reduction of protein methionine residues is an important antioxidant mechanism. Mol Cell Biochem 2002; 234-235 (1-2): 3-9.
122. Ames BN. Endogenous DNA damage as related to cancer and aging. Mutat Res 1989; 214: 41-6.
123. Cadet J, Delatour T, Douki T, Gasparutto D, Pouget JP, Ravanat JL, et al. Hydroxyl radicals and DNA base damage. Mutat Res Fundam Mol Mech Mutagen 1999; 424: 9-21.
124. Valko M, Morris H, Cronin MT. Metals, toxicity and oxidative stress. Curr Med Chem 2005; 12 (10): 1161-208.
125. Henle ES, Linn S. Formation, prevention and repair of DNA damage by iron/hydrogen peroxide. J Biol Chem 1997; 272: 19095-98.
126. Beckman KB, Ames BN. Endogenous oxidative damage of mtDNA. Mutat Res 1999; 424: 51-8.
127. Wang D, Kreutzer DA, Essigmann JM. Mutagenicity and repair of oxidative DNA damage: insights from studies using defined lesions. Mutat Res Fundam Mol Mech Mutagen 1998; 400: 99-115.
128. Kreutzer DA, Essigmann JM. Oxidized, deaminated cytosines are a sources of C T transitions in vivo. Proc Natl Acad Sci USA, 1998; 95: 3578-82.
129. Cheng KC, Cahill DS, Kasai H, Nishimura S, Loeb LA. 8-hydroxyguanine, an abundant form of oxidative DNA damage, causes G T and A C substitutions. J. Biol Chem 1992; 267: 166-72.
130. Le XC, Xing JZ, Lee J, Leadon SA, Weinfeld M. Inducible repair of thymine glycol detected by an ultrasensitive assay for DNA damage. Science 1998; 280: 1066-9.
131. Yau TM. Mutagenicity and cytotoxicity of malondialdehyde in mammalian cells. Mech Ageing Dev 1979; 11: 137-44.
132. Kocić G, Pavlović D, Crossed D signorCrossed d signević VB, Bjelaković G, Stojanović I. Role of nitric oxide and peroxynitrite in apoptosis relation to endonuclease activity. Jugoslov Med Biohem 2003; 22 (2): 93-100.
133. Marnett LJ. Lipid peroxidation-DNA damage by malondialdehyde. Mutat Res 1999; 424: 83-95.
134. Wallace SS. Enzymatic processing of radiation-induced free radical damage in DNA. Radiat Res 1998; 150: S60-79.
135. Dizdaroglu M, Jaruga P, Birincioglu M, Rodriguez H. Free radical-induced damage to DNA: mechanisms and measurement. Free Radic Biol Med 2002; 32: 1102-15.
136. Halliwell B. Effect of diet on cancer development: is oxidative DNA damage a biomarker? Free Radic Biol Med 2002; 32: 968-74.
137. Malins DC, Haimanot R. Major alterations in the nucleotide structure of DNA in cancer of the female breast. Cancer Res 1991; 51: 5430-2.
138. Nair J, Carmichael PL, Fernando RC, Phillips DH, Strain AJ, Bartsch H. Lipid peroxidation-induced etheno-DNA adducts in the liver of patients with the genetic metal storage disorders Wilson's disease and primary hemochromatosis. Cancer Epidemiol Biomarkers Prev 1998; 7: 435-40.
139. Poulsen HE, Loft S, Prieme H, Vistisen K, Lykkesfeldt J, Nyyssonen K, et al. Oxidative DNA damage in vivo: relationship to age, plasma antioxidants, drug metabolism, glutathione-S-transferase activity and urinary creatinine excretion. Free Radic Res 1998; 29: 565-71.
140. http://www.assaydesigns.com.
141. http://www.kamiyabiomedical.com.
142. http://www.dojindo.com.newsletter/review_vol2.htlm.
143. Čolak E, Srećković-Dimitrijević V, Crossed D signorCrossed d signević PB, Stanković S, Majkić-Singh N, Lalić K, et al. The influence of type and duration of cardiovascular complications on antioxidative parameter values in type 2 diabetic patients. JMB 2007; 26 (1): 10-6.